American Society of Hematology

ASH is the leader in representing the interests of scientists and clinicians working in the field of hematology on Capitol Hill and within federal agencies concerned with the study and treatment of blood-related diseases.


SCD Patient Resources 

Sickle Cell Disease Initiative

A multi-faceted initiative to identify the highest priority actions needed to improve the outcomes for individuals with SCD in the U.S. and globally.

Fight for Hematology Advocacy Landing 

Support Medical Research

Urge your members of Congress to support continued medial research funding.

Advocacy Leadership Institute

Provides opportunities to learn more about advocacy, health policy, and the legislative process, and to become engaged in the Society’s activities.

Congressional Fellowship

Provides education about the policy making process, including Congress’ relationship to the hematology community.

MACRA Resources

Get an overview of the Medicare Access and CHIP Reauthorization Act (MACRA) and its impact on hematology.

Drug Access Issues

Keep informed of newly approved therapies, safety and prescription matters, and shortages of critical hematologic drugs.

  • President’s Proposed FY 2018 Budget Seeks Massive Cuts to NIH

    President Trump’s fiscal year (FY) 2018 budget outline seeks massive cuts to federal non-defense discretionary (NDD) programs including the National Institutes of Health (NIH). Your elected officials need to hear from you about the importance of sustained and predictable NIH funding.

  • Contact Your North Carolina State Senator in Support of H. 206

    The Cancer Treatment Fairness Act (H.206) would require any health plan that provides coverage for cancer chemotherapy treatment to provide coverage for orally administered and self-injectable anticancer medications at a cost no less favorable than the cost of IV, port-administered, or injected anticancer medications. It is important you reach out to ask for your North Carolina state Senator's support.

  • Urge your Representative to Support the Cancer Drug Parity Act

    Legislation has been introduced in the U.S. House of Representatives that would ensure that patients enrolled in certain federally regulated health plans have access and insurance coverage for all anti-cancer regimens. Your Senators and Representative need to cosponsor these bills in order for them to be considered by the full Congress.

View all action alerts
  • NCATS Seeking Information on Opportunities and Challenges for Platform Vector Human Gene Therapy Trials in Rare Diseases

    The National Center for Advancing Translational Sciences (NCATS) released a request for information soliciting input on the use of viral vectors as platforms for therapeutic gene delivery to specific organs or cell types, and how such platforms might be developed most efficiently in clinical trials for the treatment of multiple diseases.

  • Congress Changes Stance on ACA Repeal and Replace

    On July 13, 2017, the U.S. Senate released an updated version of the Better Care Reconciliation Act (BCRA), legislation to repeal large provisions of the Affordable Care Act (ACA).

  • DEA Eliminates Grace Period for Registration Renewal

    Through a notice on its website, the Drug Enforcement Administration (DEA) recently announced significant changes to its registration renewal process. Effective January 1, 2017, the DEA is eliminating the informal grace period which the agency has previously allowed for registrants to renew their registrations. 

  • CMS Announces End to Medicare Part B Drug Payment Model

    On December 15, 2016, the Centers for Medicare and Medicaid Services (CMS) announced the cancellation of Medicare Part B Drug Payment Model.  CMS initially proposed the demonstration on March 8, 2016 to test new models in how physician-administered drugs are paid under the Medicare program.

View all policy news
back to top